Follow-up study for people treated with gene therapy for ADA-SCID
Part of Genetic & congenital, Hormones & metabolism, Immune system & allergy clinical trials.
This is a follow-up (no new treatment) study for people who previously received a gene therapy made from their own cells for ADA-SCID. It mainly tracks long-term safety and whether a marker showing the gene change can still be found.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You previously received ADA-SCID gene therapy using your own cells (EFS-ADA LV/OTL-101 program).
- Your study doctor can still detect a lasting “gene marking” signal in you.
- You (or your parent/legal guardian) can understand and sign informed consent.
- This is observational, meaning no extra study treatment is added.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a gene therapy using a lentivirus to give missing immune system instructions in children with X-linked SCID (SCID-X1). It also uses a low dose of targeted chemotherapy (busulfan) to help the new genes work, and it requires long-term follow-up for safety.
This study monitors the long-term health of people with Glycogen Storage Disease Type Ia who have already received the gene therapy DTX401, either in a previous clinical trial or after it was approved. The goal is to gather more information about their condition over time.
This study checks on people who already received the gene therapy EG110A in a previous trial. It looks at long-term safety and any lasting effects, to make sure the treatment remains safe over time.
This study tests a new gene therapy that adds a working copy of the missing ADA gene to your own blood stem cells, helping your immune system fight infections. It is for people with ADA-SCID who have not had a prior transplant.
This study is a long-term follow-up for people who already received gene therapy for sickle cell disease in a specific sponsor’s clinical trial. It helps researchers watch for long-term safety and outcomes over time.
This study follows people long-term after receiving a specific gene-cell treatment called AGT103-T. It helps researchers check long-term safety and outcomes, which can guide future care for others.
Hear when a new Severe Combined Immunodeficiency (SCID) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.